Status:
UNKNOWN
Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome
Lead Sponsor:
Mahidol University
Collaborating Sponsors:
Siriraj Hospital
Conditions:
Hand-Foot Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Hand foot skin reaction (HFS) from capecitabine is one of the most common adverse events from capecitabine. Urea cream has been proved its benefit to prevent HFS from sorafenib. Prior study using urea...
Detailed Description
The patients who is planned to receive capecitabine for at least 3 cycles were enrolled in the study. The patients were randomized to receive 10% urea cream or standard measure. The patients were foll...
Eligibility Criteria
Inclusion
- \- patients who has plan to receive capecitabine at the dosage of at least 2000 mg/m2 D1-14 every 21 days for at least 3 cycles
Exclusion
- preexisting neuropathy which was severe than grade 2
- history of allergy to urea cream
- patients with previous use of capecitabine 2000 mg/m2
- patients who has prior routinely used of urea cream
Key Trial Info
Start Date :
December 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT05348278
Start Date
December 20 2021
End Date
August 1 2023
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of medical oncology, department of medicine Siriraj Hospital
Bangkok, Thailand, 10700